PREMIER Biosoft Acquires ProteoIQ
News Mar 12, 2013
PREMIER Biosoft has announced the acquisition of ProteoIQ from NuSep a publicly listed Australia firm. With ProteoIQ, PREMIER Biosoft now offers a broad spectrum of products for mass spectrometry based "Omics" and "Imaging" studies to the research community.
With this acquisition, PREMIER Biosoft enters the attractive proteomics market, after successfully launching best-in-class products for the lipidomics, glycomics and MALDI imaging markets.
ProteoIQ is a software tool for proteomic data analysis that streamlines the process of statistical validation, protein quantification and comparative proteomics on one platform.
It supports validation of the proteins identified by other database search tools such as Mascot, SEQUEST, or X!Tandem.
ProteoIQ incorporates the False Discovery Rate and Protein Probability approaches for statistical validation of identified proteins.
It performs quantitative analysis via spectral counting, precursor intensity, iTRACQ, TMT, SILAC and iCAT workflows.
Users can quickly perform differential analysis of results across biological samples thereby facilitating identification of putative biomarkers.
"For the rapidly growing proteomics market, ProteoIQ is a strategic fit to PREMIER Biosoft's existing mass spec product offering and helps consolidate our position as a leader for providing informatics tools for mass spectrometry," said Arun Apte, CEO, PREMIER Biosoft.
This is the second acquisition for the company, after completing the acquisition of Redasoft in August 2011.
Arrow Poison Potential Male Birth ControlNews
Women have many options for oral contraceptives that are safe, effective and reversible, but despite decades of research, men have none. Now, scientists report a rat study that shows they finally have a good lead for a male birth control pill. It's based on ouabain, a plant extract that African warriors and hunters traditionally used as a heart-stopping poison on their arrows.READ MORE
Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule InhibitorsNews
A new original research article presents a fast, sensitive, and robust methodology for screening small molecule inhibitors against CD73/Ecto-5'-Nucleotidase, a promising target for developing anti-cancer drugs.READ MORE